A phase I, randomized, double-blind, placebo-controlled, four-way cross-over study to evaluate the analgesic effects of TRV045 in healthy adults

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-501804-80-00

Acronym

CP045-1002

Enrollment

Registered

2022-11-15

Start date

2022-11-17

Completion date

2023-06-21

Last updated

2023-03-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute and chronic neuropathic pain secondary to diabetic peripheral neuropathy

Brief summary

Pharmacodynamic measurements with the UVB pain model

Detailed description

Pharmacokinetic endpoints, Safety and tolerability endpoints

Interventions

DRUGTRV045 placebo

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
Pharmacodynamic measurements with the UVB pain model	—

Secondary

Measure	Time frame
Pharmacokinetic endpoints, Safety and tolerability endpoints	—

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026